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Chlamydiae replicate intracellularly in a vacuole called an inclusion. Chlamydial-infected host cells are protected from
mitochondrion-dependent apoptosis, partly due to degradation of BH3-only proteins. The host-cell adapter protein 14-
3-3b can interact with host-cell apoptotic signaling pathways in a phosphorylation-dependent manner. In Chlamydia
trachomatis-infected cells, 14-3-3b co-localizes to the inclusion via direct interaction with a C. trachomatis-encoded
inclusion membrane protein. We therefore explored the possibility that the phosphatidylinositol-3 kinase (PI3K)
pathway may contribute to resistance of infected cells to apoptosis. We found that inhibition of PI3K renders C.
trachomatis-infected cells sensitive to staurosporine-induced apoptosis, which is accompanied by mitochondrial
cytochrome c release. 14-3-3b does not associate with the Chlamydia pneumoniae inclusion, and inhibition of PI3K does
not affect protection against apoptosis of C. pneumoniae-infected cells. In C. trachomatis-infected cells, the PI3K
pathway activates AKT/protein kinase B, which leads to maintenance of the pro-apoptotic protein BAD in a
phosphorylated state. Phosphorylated BAD is sequestered via 14-3-3b to the inclusion, but it is released when PI3K is
inhibited. Depletion of AKT through short-interfering RNA reverses the resistance to apoptosis of C. trachomatis-
infected cells. BAD phosphorylation is not maintained and it is not recruited to the inclusion of Chlamydia muridarum,
which protects poorly against apoptosis. Thus, sequestration of BAD away from mitochondria provides C. trachomatis
with a mechanism to protect the host cell from apoptosis via the interaction of a C. trachomatis-encoded inclusion
protein with a host-cell phosphoserine-binding protein.
Citation: Verbeke P, Welter-Stahl L, Ying S, Hansen J, Ha¨cker G, et al. (2006) Recruitment of BAD by the Chlamydia trachomatis vacuole correlates with host-cell survival. PLoS
Pathog 2(5): e45. DOI: 10.1371/journal.ppat.0020045
Introduction
Chlamydia trachomatis is the leading cause of bacterial
sexually transmitted diseases worldwide; strains of C. tracho-
matis responsible for ocular infections lead to blindness, while
Chlamydia pneumoniae causes pneumonia in humans and may
accelerate atherosclerosis [1–6].
All Chlamydia species are intracellular pathogens that
primarily infect epithelial mucosa [7]. Chlamydiae spend
most of their developmental cycle within a membrane-bound
vacuole, or inclusion, which avoids fusion with host-cell
lysosomes. Despite their intravacuolar localization, the
bacteria interact with the host cell to ensure that their
inclusion remains a safe haven for replication [8], but at the
same time allows for acquisition of essential nutrients from
the host-cell cytosol [9].
Many membrane-trafﬁcking and metabolic changes in the
host cell are thought to be controlled by chlamydial proteins
that are inserted into the inclusion membrane or secreted
into the host cytosol. Similar to other Gram-negative
bacterial pathogens, Chlamydia species possess a specialized
type III secretion apparatus that behaves as a molecular
syringe, enabling the bacteria to inject virulence factors from
the bacteria into the host cytosol [10,11]. The metabolic
demands made on the host cell by the growing inclusion
[9,12] may activate a number of stress-related signaling
pathways, including mitogen-activated protein kinases (MAP
kinases or ERKs) [13–16]. Signiﬁcantly, many stress-respon-
sive pathways are involved in adaptation to environmental
changes and affect apoptosis.
Apoptosis is required for the development of metazoans
and is crucial for the maintenance of cellular homeostasis in
mammals [17]. Microbial pathogens can inhibit or stimulate
apoptosis of the infected cell [18,19]. In some cases, infection
can result in both induction and inhibition of apoptosis at
different stages of the infection cycle [20]. Likewise, it has
been proposed that chlamydiae may induce cell death at the
end of the infection cycle, but inhibit apoptosis at the
beginning of the cycle [21].
The ﬁrst reports of an anti-apoptotic effect of chlamydial
infection showed that infection of epithelial cells and
macrophages with C. trachomatis or C. pneumoniae protects
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against externally applied insults that induce apoptosis in
uninfected cells [22–25]. These studies demonstrated that
chlamydial infection prevents the release of cytochrome c
from mitochondria and subsequent activation of caspases,
suggesting that the apoptotic pathway may be blocked
upstream from mitochondria. This view was reinforced by
the observation that Chlamydia-infected cells are resistant to
apoptotic pathways that rely on a mitochondrial ampliﬁca-
tion step, but not when caspases are activated directly [26].
More recently, it was shown that part of the resistance to
apoptosis is due to degradation in infected cells of pro-
apoptotic BH3-only proteins, including BIM, PUMA, and
BAD [27–29]. These mediators lie upstream of mitochondria,
where they activate BAX and BAK, which oligomerize on
mitochondria and stimulate cytochrome c release [30].
Nonetheless, the possibility that stress-dependent or other
signal transduction pathways, in parallel with BH3-only
protein degradation, may contribute to protection against
apoptosis has not been investigated. Importantly, the
chlamydial inclusion membrane contains abundant trans-
membrane proteins encoded by the chlamydial genome,
named Inc proteins, which participate in the development of
the chlamydial inclusion [31]. A yeast two-hybrid analysis with
one of the proteins, IncG, has shown that it interacts with a
host cell protein, 14-3-3b [32]. This adapter protein is
normally distributed in the cytosol, but in C. trachomatis-
infected cells, it interacts and co-localizes with IncG [32]. The
function for the IncG/14-3-3b interaction was not elucidated,
but in uninfected cells, 14-3-3b can interact with several host-
cell signaling pathways in a phosphorylation-dependent
manner, including those involved in cell-cycle regulation,
membrane trafﬁcking, and apoptosis. The 14-3-3 isoforms
can form homo- and heterodimers both in vivo and in vitro,
which is thought to facilitate their interaction with different
components of signaling pathways [33,34]. Signiﬁcantly, in
the presence of survival factors, cytosolic 14-3-3 proteins
sequester phosphorylated BAD away from its targets in the
mitochondria [35,36]. In the absence of survival factors, BAD
is dephosphorylated and associates with mitochondria,
resulting in release of cytochrome c and cell death. BAD
itself is phosphorylated by AKT/protein kinase B (PKB), which
is activated in the presence of survival factors by phospha-
tidylinositol-3 kinase (PI3K) [35–37].
The goal of this study was therefore to determine whether
stress-induced MAP kinase pathways or PI3K may contribute
to resistance of C. trachomatis-infected cells to apoptosis. We
found that infection leads to activation of the PI3K pathway,
which results in phosphorylation of BAD and its recruitment
to chlamydial inclusions that express IncG. As our results
revealed a predominant role for the PI3K pathway, we
evaluated involvement of AKT through RNA interference
and found that AKT plays an essential role in this protection.
Our results further indicate that the PI3K pathway plays no
role in protection against apoptosis in the absence of BAD
phosphorylation or during infection with C. pneumoniae, which
does not express IncG.
Results
The Lymphogranuloma Venereum Strain of C. trachomatis
Protects Infected Cells against Staurosporine-Induced
Apoptosis through a PI3K-Dependent Pathway
As infection of HeLa cells with the lymphogranuloma
venereum (LGV)/L2 serovar has been reported to inhibit
apoptosis in infected cells [22,26,27], we ﬁrst measured the
response of C. trachomatis-infected epithelial cells to treat-
ment with the apoptosis inducer, staurosporine (STS). Thus,
cells were infected with the LGV/L2 serovar and then treated
with STS before immunoﬂuorescence staining using the DNA
dye, Hoechst, to reveal segmented (apoptotic) nuclei; TUNEL
(to identify apoptotic nuclei with fragmented DNA); and an
anti-Chlamydia antibody to identify infected cells. While many
apoptotic nuclei were present among uninfected cells, very
few cells containing Chlamydia inclusions had apoptotic
nuclei. Consistent with previous results [22,27], more than
95% of the cells containing Chlamydia inclusions were
resistant to STS-induced apoptosis (Figure 1).
The LGV/L2 serovar of C. trachomatis produces a trans-
membrane protein, IncG, which localizes to the inclusion
membrane and interacts speciﬁcally with 14-3-3b [32]. In
uninfected cells in the presence of survival signals, the PI3K
pathway leads to phosphorylation and activation of AKT/
PKB, and subsequent phosphorylation of BAD, which in its
phosphorylated form is sequestered in the cytoplasm by
cytosolic 14-3-3 [35,36]. In order to explore the possibility
that 14-3-3 recruitment by the Chlamydia inclusion may
increase resistance to apoptosis, cells that had been infected
with the LGV/L2 serovar were incubated with a PI3K
inhibitor (LY294002) before treatment with STS. Under
conditions in which STS-mediated apoptosis was inhibited
more than 95% by C. trachomatis infection, over a third of the
infected cells that had been pretreated with the PI3K
inhibitor underwent apoptosis (Figure 1).
The PI3K inhibitor was added 24 h prior to treatment with
STS (8 h post-infection) (Figure 1) or 6 h prior to treatment
with STS (26 h post-infection) (unpublished data). Both
protocols gave similar results, suggesting that the PI3K
inhibitor has its effect on apoptosis at a post-entry step.
To investigate the speciﬁcity of PI3K-dependent resistance
to apoptosis, infected cells were treated separately with
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Synopsis
Chlamydia trachomatis is the most common cause of sexually
transmitted bacterial infections in humans. These bacteria survive
and replicate within a vacuole in the infected cell called an inclusion,
producing up to a thousand bacteria per inclusion within a day of
infection. Despite the large size of the inclusion, the infected cell
survives long enough for the pathogens to complete their infection
cycle and then infect new host cells. The researchers describe a
novel mechanism for protection of the host cell by Chlamydia,
namely activation of enzymes involved in host-cell survival. These
enzymes, called kinases, cause the phosphorylation and inactivation
of a protein, BAD, which can promote ‘‘cell suicide’’ (apoptosis) of
uninfected cells. BAD phosphorylation is accompanied by recruit-
ment of BAD to the chlamydial inclusion, where BAD binds to a
cellular adapter protein, 14-3-3b. The adapter protein, in turn, is
attracted to the inclusion by a membrane protein produced by
Chlamydia. Thus, the chlamydial inclusion sequesters BAD away
from mitochondria, where BAD could induce host-cell apoptosis.
The cross talk between chlamydiae and host-cell signaling pathways
demonstrates a novel mechanism of pathogen modulation of host-
cell biology, and represents a potential therapeutic target for
blocking infection by this prevalent pathogen.
inhibitors that target components of different anti-apoptotic
pathways, such as JNK1/2 (SP600125), P38 (SB203580), mTOR
(rapamycin), and synthesis of heat shock proteins (KNK437),
including hsp70 [38,39]. Using trypan blue exclusion assays,
we veriﬁed that the drugs were not toxic to uninfected cells at
the concentrations used. With the possible exception of the
JNK1/2 inhibitor, which increased slightly the level of STS-
induced apoptosis, none of the inhibitors had a signiﬁcant
effect on resistance to apoptosis (Figure 1). Thus, the PI3K
pathway has a predominant role in protecting infected cells
against STS-mediated apoptosis.
To determine whether the PI3K pathway is involved in
protection of C. pneumoniae-infected cells from apoptosis, we
measured resistance to STS-induced apoptosis of C. pneumo-
niae-infected cells in the presence and absence of LY294002
and found no change in the level of protection (unpublished
data). Thus, while other mechanisms such as BH3-only
protein degradation may provide protection against apopto-
sis of C. pneumoniae-infected cells, the PI3K pathway does not
contribute to resistance. Genome sequencing has revealed an
IncG homolog is present in C. trachomatis L2 but not in C.
pneumoniae [11,40,41]. Consistent with this ﬁnding, the IncG-
binding adaptor 14-3-3b is localized on C. trachomatis L2
inclusions but not on C. pneumoniae inclusions [32]. Consid-
ered together with our ﬁndings, these data indicate that
sequestration of 14-3-3b to the inclusion is required for PI3K-
dependent protection.
LY294002 Pretreatment Increases Cytochrome c Release
in C. trachomatis-Infected Epithelial Cells
The release of cytochrome c is a critical step in the
mitochondrial pathway to apoptosis, which is triggered by
STS. We next tested whether the PI3K-mediated protection
was located upstream or downstream of cytochrome c release.
In the absence of apoptotic stimuli, cytochrome c is localized
in mitochondria. Typical results, shown in Figure 2A, indicate
that less than 10% of uninfected cells retained cytochrome c
in their mitochondria after treatment with STS. Under the
same conditions, more than 60% of STS-treated C. trachoma-
tis-infected cells retained their mitochondrial pool of
cytochrome c (Figure 2B). However, the percentage of
infected cells showing retention of mitochondrial cyto-
chrome c decreased signiﬁcantly when those cells were
preincubated with LY294002 before incubation with STS
(Figure 2B). These results suggest that PI3K-dependent
inhibition of apoptosis in C. trachomatis-infected cells is
associated with the ability of the cells to maintain an intact
mitochondrial membrane. The pro-survival activity of PI3K/
AKT is therefore localized upstream of mitochondrial
cytochrome c release.
Figure 1. Signal-Transduction Pathways Involved in Resistance of C.
trachomatis-Infected Cells against Apoptosis
All cells were infected with C. trachomatis at an MOI of 1.0 for 32 h and
then treated overnight with 2 lM STS. In uninfected cells that had been
treated with STS under the same conditions, 83 6 10% of the cells had
apoptotic nuclei. Inhibitors were added 24 h before STS treatment, as
indicated in the inset. The inhibitor concentrations (and targeted
mediators) were: 50 lM LY294002 (PI3K), 10 lM SB203580 (P38), 10
lM U0126 (MEK5), 10 lM SP600125 (JNK1/2), 5 nM rapamycin (mTOR),
and 50 lM KNK437 (heat shock proteins). The ‘‘control (no STS)’’
contained infected cells, while ‘‘control w/STS’’ contained infected cells
that were incubated with buffer without inhibitor and then treated with
STS. DNA was revealed by Hoechst staining, and values are expressed as
the % of infected cells that had apoptotic nuclei. The average and SD
were calculated from the values obtained from at least 50 microscope
fields. The experiment was performed on three separate days, and results
from a representative experiment are shown.
DOI: 10.1371/journal.ppat.0020045.g001
Figure 2. Cytochrome c Release from C. trachomatis-Infected Cells
Treated with the PI3K Inhibitor
Cells were infected with C. trachomatis at an MOI of 1.0 for 26 h (B) or
mock-infected (A), and then incubated with control buffer or 50 lM
LY294002 (LY) or control buffer for 6 h before treating with 2 lM STS
overnight. Cells were then collected for cytofluorimetry, permeabilized
with detergent, and incubated with anti-cytochrome c antibody, as
described in Materials and Methods. Cytochrome c was released from
uninfected cells that were treated with STS (A), but was retained in
infected cells treated with STS (B). However, cytochrome c was released
in infected cells that had been pre-incubated with LY294002 before STS
treatment (B). One experiment of two representative experiments
performed on separate days is shown.
DOI: 10.1371/journal.ppat.0020045.g002
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AKT Activation Is Downstream from PI3K Activation
during C. trachomatis Infection
In order to further elucidate the anti-apoptotic mecha-
nisms induced by infection, we measured the phosphoryla-
tion status of an essential survival-signaling mediator that is
downstream from PI3K, the serine/threonine kinase, AKT/
PKB. In several cell lines, PI3K phosphorylates and thereby
activates AKT, which then promotes survival through
phosphorylation of multiple targets [35,36]. We thus meas-
ured phosphorylation by immunoblots using antibodies
against a phosphorylation site of AKT (residue Ser473) that
leads to AKT activation in epithelial cells under different
conditions.
AKT phosphorylation/activation increased after a 24-h
infection with C. trachomatis, and decreased back to basal
levels by 48 h after infection (Figure 3). STS treatment did not
affect the AKT phosphorylation level in uninfected or
infected cells. In cells infected for 24 h that were then
preincubated for 6 h with LY294002 (before incubation with
STS or control buffer overnight), essentially all the AKT
became dephosphorylated (Figure 3). These results suggest
that Chlamydia infection leads to PI3K activation, which is
essential for subsequent phosphorylation and activation of
the downstream effector, AKT.
In order to rule out the possibility that the PI3K inhibitor,
LY294002, may have nonspeciﬁc effects and to conﬁrm a role
for AKT in the resistance to apoptosis, we inhibited AKT
expression speciﬁcally in the epithelial cells by RNA
interference. 48 h after transfection with AKT siRNA, more
than 70% of the protein levels of AKT were reduced in
uninfected cells, as veriﬁed by Western blotting (Figure 4,
inset); and we veriﬁed that AKT siRNA by itself did not
induce apoptosis of uninfected cells (unpublished data). The
epithelial cells were ﬁrst transfected with AKT siRNA,
infected with C. trachomatis, and then treated with STS. In
untransfected cells that contained chlamydial inclusions, very
few were sensitive to STS-induced apoptosis determined by
ﬂuorescence microscopic examination for nuclear condensa-
tion. In contrast, more than half of the AKT siRNA
transfected cells that contained chlamydial inclusions ex-
hibited apoptosis after treatment with STS (Figure 4). Taken
together, these results suggest that AKT plays a major role in
protection against apoptosis of Chlamydia-infected cells.
PI3K Activation Leads to BAD Phosphorylation in Epithelial
Cells Infected with C. trachomatis
AKT has been shown to phosphorylate BAD on residue
Ser136, which causes BAD to lose its pro-apoptotic activity
[35,36]. In order to determine whether phosphorylated BAD
could play a role in resistance to apoptosis during C.
trachomatis infection, we increased BAD protein-expression
by transfecting epithelial cells with a BAD eukaryotic
expression plasmid prior to infection and observing the
phosphorylation of BAD by Western blotting. Although BAD
was expressed at high levels in both infected and uninfected
cells, the sensitivity to STS-induced apoptosis of the cells was
similar to the sensitivity of cells expressing normal levels of
BAD (unpublished data).
The total amount of BAD decreased in infected cells after
32 h of infection (Figure 5A), consistent with our previous
results obtained at a higher multiplicity of infection (MOI)
with cells that expressed only endogenous BAD [27,28]. There
was little basal phosphorylation in uninfected cells, but BAD
phosphorylation increased 8 h post-infection, peaked be-
tween 24–32 h post-infection, and decreased thereafter
(Figure 5A). A similar time course for BAD phosphorylation
Figure 3. AKT Phosphorylation in Cells during Apoptosis of C.
trachomatis-Infected Cells
Cells were infected with C. trachomatis at an MOI of 1.0 for 24 or 48 h, or
mock-infected, and then incubated with 50 lM LY294002 (LY) or control
buffer for 6 h before treating with control buffer or 2 lM STS overnight.
Cells were then collected for Western immunoblotting and analyzed for
phosphorylation of AKT on residue Ser473, as described in Materials and
Methods. STS treatment by itself did not affect AKT Ser473 phosphor-
ylation in infected cells, but LY294002 caused AKT Ser473 to become
partially dephosphorylated. This residue became dephosphorylated
almost completely when LY294002 was combined with STS in infected
cells. One experiment of two representative experiments performed on
separate days is shown.
DOI: 10.1371/journal.ppat.0020045.g003
Figure 4. Effect of Inhibition of AKT Expression on Apoptosis of C.
trachomatis-Infected Cells
Cells were transfected with AKT siRNA (þ) or control reagents () for 8 h,
infected with C. trachomatis at an MOI of 1.0 for 32 h, and then incubated
with 2 lM STS or control buffer overnight. The efficiency of transfection
with AKT siRNA in epithelial cells was monitored by co-transfecting with
fluorescein-labeled irrelevant siRNA, which showed that approximately
80% of cells were transfected during the experiments (unpublished
data). DNA was revealed with Hoechst and Chlamydia with anti-
Chlamydia antibody. The extent of nuclear condensation was measured
only in cells that contained Chlamydia vacuoles. No nuclear condensa-
tion was observed in infected cells that expressed normal levels of AKT,
but STS led to nuclear condensation in infected cells that had been
transfected with AKT siRNA. One experiment of two representative
experiments performed on separate days is shown.
Inset: Inhibition of AKT expression in epithelial cells by RNA interference.
Cells were transfected with siRNA for AKT or controls. After 48 h, the cells
were harvested and AKT protein levels were measured by Western
immunoblotting. The control reagents did not affect AKT expression, and
AKT siRNA had no effect on the expression of another protein, the P42
MAP kinase.
DOI: 10.1371/journal.ppat.0020045.g004
PLoS Pathogens | www.plospathogens.org May 2006 | Volume 2 | Issue 5 | e450411
Survival of Chlamydia-Infected Cells
was observed in infected cells expressing only endogenous
BAD (Figure 5B), suggesting that the total level of BAD
protein does not affect the kinetics of BAD phosphorylation.
IncG is also expressed by the genome of Chylamdia
muridarum, and 14-3-3b is recruited to C. muridarum inclusions
[32]. However, C. muridarum infection protects the host cell
against apoptosis poorly, if at all [42,43]. To investigate
whether BAD might interact with inclusion-bound 14-3-3b in
C. muridarum-infected cells, cells over-expressing BAD were
infected with C. muridarum and the level of AKT and BAD
phosphorylation was measured (Figure 5C). There may be an
increase in the extent of AKT phosphorylation in infected
cells, but the level of BAD phosphorylation peaked within 5 h
of infection and decreased by 8 h after infection (Figure 5C).
Almost no phosphorylated BAD remained by 16 h of
infection. Thus, no phosphorylated BAD remains in cells
infected with C. muridarum at times when cells infected with C.
trachomatis and C. pneumoniae begin to exhibit resistance to
apoptosis [22,25,27], suggesting that rapid dephosphorylation
of BAD may account for the poor protection against
apoptosis conferred by C. muridarum infection.
The potential role of the PI3K pathway in activating BAD
in cells infected with C. trachomatis was investigated by
Western blot. Phosphorylated BAD was detected in both
infected and uninfected cells, but disappeared after STS
treatment of uninfected cells (Figure 6). Moreover, the levels
Figure 5. Time Course of BAD Phosphorylation during C. trachomatis or
C. muridarum Infection
(A) Epithelial cells were transfected with a BAD expression plasmid prior
to infection, as described in Materials and Methods. Cells over-expressing
BAD were infected with C. trachomatis at an MOI of 1.0 for the indicated
times. Cells were then collected for Western immunoblotting and
analyzed for AKT phosphorylation (top row), total AKT protein (second
row), total BAD protein (third row), phosphorylation of BAD on residue
Ser136 (fourth row), or actin (bottom row), as described in Materials and
Methods. Chlamydia infection at this MOI led to a decrease in the level of
total BAD protein after 32 h of infection. For AKT residue Ser473, there
was a low level of phosphorylation in uninfected cells (time 0), but there
was a noticeable increase in phosphorylation for both AKT and BAD after
16 h of infection. Phosphorylation levels decreased after 32 h of infection
for both BAD and AKT. Chlamydia infection had no effect on actin
protein levels (bottom row). One experiment of three representative
experiments performed on separate days is shown.
(B) Cells expressing endogenous levels of BAD were infected with C.
trachomatis at an MOI of 1.0 for the indicated times. Cells were then
collected for Western immunoblotting and analyzed for phosphorylation
of BAD on residue Ser136 (top row) or actin (bottom row). The time
course of BAD phosphorylation in cells expressing only endogenous BAD
was similar to the time course in cells that had been transfected with the
BAD expression plasmid (A). One experiment of two representative
experiments performed on separate days is shown.
(C) Cells over-expressing BAD were infected with C. muridarum at an MOI
of 1.0 for the indicated times. Cells were then collected for Western
immunoblotting and analyzed for AKT phosphorylation (top row), total
AKT protein (second row), total BAD protein (third row), phosphorylation
of BAD on residue Ser136 (fourth row), or actin (bottom row). Chlamydia
infection at this low MOI led to a decrease in the level of total BAD
protein after 32 h of infection. BAD was phosphorylated significantly
Figure 6. Effect of PI3K on BAD Phosphorylation during C. trachomatis
Infection
Cells over-expressing BAD were infected with C. trachomatis at an MOI of
1.0 for 26 h or mock-infected, and then incubated with 50 lM LY294002
(LY) or control buffer for 6 h before treating with 2 lM STS overnight.
Cells were then collected for Western immunoblotting and analyzed for
total BAD protein (top row), phosphorylation of BAD on residue Ser136
(middle row), or total P42 MAP kinase protein (bottom row), as described
in Materials and Methods. C. trachomatis infection led to a decrease in
the level of BAD, which was further decreased by STS treatment. Pre-
incubation with LY294002 did not further alter the level of total BAD (top
row). STS-treatment of uninfected cells caused complete dephosphor-
ylation of BAD, but BAD remained phosphorylated after STS-treatment of
infected cells (middle row). However, pre-incubation of infected cells
with LY294002 before treatment with STS resulted in complete
dephosphorylation of BAD (middle row). Infection had no effect on
total P42 MAP kinase protein levels (bottom row). One experiment of
three representative experiments performed on separate days is shown.
DOI: 10.1371/journal.ppat.0020045.g006
within 5 h of infection, but phosphorylation levels decreased by 8 h post-
infection and were not measurable after 1 d of infection. One experiment
of three representative experiments performed on separate days is
shown.
DOI: 10.1371/journal.ppat.0020045.g005
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of total BAD decreased with STS treatment in both
uninfected and infected cells, consistent with previous studies
showing cleavage of BAD during cell death [44]. Conversely,
the level of phosphorylated BAD remained high in infected
cells treated with STS, unless the cells were pretreated with
LY294002 (Figure 6). Thus, infection inhibits BAD dephos-
phorylation, which is downstream from PI3K/AKT activation.
We have recently reported that C. trachomatis infection
leads to degradation of several pro-apoptotic BH3-only
proteins [27,28]. In order to determine if inhibition of PI3K
by LY294002 speciﬁcally affected degradation of BH3-only
proteins, we infected epithelial cells with C. trachomatis. C.
trachomatis infection resulted in degradation of both BIM and
BAD, but the PI3K inhibitor had no effect on infection-
induced degradation of either BIM or BAD (unpublished
data), suggesting that phosphorylation of BAD may be acting
as an alternate anti-apoptotic pathway, in parallel with
induction of BH3-only protein degradation.
Infection with C. trachomatis Causes Phosphorylated BAD
to Become Localized on Chlamydial Inclusions
In the absence of apoptotic stimuli, BAD is uniformly
distributed in the cytosol (unpublished data). However, in
infected cells, most BAD is localized to the Chlamydia
inclusion, in the presence or absence of STS, suggesting that
the pro-apoptotic protein is sequestered by the inclusion
(Figure 7A, ﬁrst and second rows). Incubation of infected cells
with LY294002 prior to STS treatment resulted in a decrease
in BAD associated with the Chlamydia inclusion, which
coincided with nuclear condensation in infected cells (Figure
7A, third row).
The adapter protein 14-3-3 binds only to BAD that is
phosphorylated [35,36]. To determine whether phosphory-
lated BAD is recruited by the Chlamydia vacuole, cells over-
expressing BAD were infected with C. trachomatis, and
phosphorylated BAD was localized by immunoﬂuorescence
using antibodies that recognize BAD phosphorylated on
residue Ser136. To exclude the possibility of artifactual co-
localization between phosphorylated BAD and chlamydiae
due to the large size of mature inclusions, cells were infected
for only 15 h. Figure 7B (top row) shows that there is co-
localization between phosphorylated BAD and the early
chlamydial inclusion. Similar results were found in cells
infected for longer times (unpublished data). In order to
examine whether phosphorylation of BAD is required for the
co-localization, the infected cells were also treated with the
PI3K inhibitor, LY294002. Longer exposures failed to reveal
co-localization between the inclusion and remaining phos-
phorylated BAD (Figure 7B, bottom row).
Given that BAD was quickly dephosphorylated during
infection with C. muridarum, we also measured the localization
of BAD in cells over-expressing BAD that were infected with
C. muridarum. Cells were infected with C. muridarum for 15 h, at
which time little BAD was still phosphorylated. There was no
co-localization between BAD and the early inclusion (Figure
7C), although similar results were also obtained with larger
inclusions (unpublished data). The PI3K inhibitor, LY294002,
had no effect on the distribution of BAD in C. muridarum-
infected cells (unpublished data).
Since BAD phosphorylation leads to sequestration of BAD
by cytosolic 14-3-3 in uninfected cells [35], and the 14-3-3b
protein has been previously shown to localize on the surface
of the C. trachomatis vacuole in infected cells [32], we examined
the distribution of 14-3-3b in infected and uninfected cells,
with or without STS treatment. As expected, 14-3-3b was
distributed uniformly in uninfected cells (unpublished data).
During C. trachomatis infection, 14-3-3b was localized in a ring
around the inclusion, in agreement with previous results [32]
(unpublished data). Interestingly, 14-3-3b remained localized
in the ring despite treatment with STS (Figure 8, top row).
But 14-3-3b distributed throughout infected cells that had
been pretreated with LY294002 before incubation with STS
(Figure 8, bottom row), which could be due in part to
condensation of the dying host-cell and fragmentation of the
inclusion. Thus, protection of C. trachomatis-infected cells
against apoptosis is due at least partly to activation of PI3K
and AKT, which correlate with BAD phosphorylation and the
sequestration of phosphorylated BAD by 14-3-3b on the
surface of the Chlamydia inclusion.
Discussion
We demonstrate here that the PI3K pathway plays a
prominent role in protecting C. trachomatis-infected cells
from apoptosis. Among different signaling pathways consid-
ered, only inhibition of the PI3K pathway removed the
protection provided by infection against apoptosis. Inhibitors
targeting JNK1/2, P38, mTOR or synthesis of heat shock
proteins were unable to reverse protection against apoptosis,
although the JNK1/2 inhibitor had a slight effect.
The PI3K pathway leads to phosphorylation of AKT, which
in C. trachomatis-infected cells remains phosphorylated even
after treatment with STS. Consistent with a role for this
pathway in resistance to apoptosis, inhibition of PI3K or
depletion of AKT causes STS-treated infected cells to die
through apoptosis, through a mechanism involving cyto-
chrome c release. AKT activation also results in BAD
phosphorylation, which can be blocked in infected cells by
incubation with the PI3K inhibitor, and with a time course
that is consistent with the appearance of protection against
apoptosis of cells infected with C. trachomatis [22]. BAD co-
localizes with the adapter protein, 14-3-3b, on the surface of
the chlamydial inclusion membrane even in infected cells that
had been treated with STS. As 14-3-3b co-localizes with the
chlamydial protein IncG on the surface of the inclusion [32],
these results suggest that this IncG-14-3-3b interaction allows
the inclusion to sequester BAD away from mitochondria,
where it could stimulate release of cytochrome c. Simulta-
neous activation of the PI3K pathway during infection
maintains BAD in its phosphorylated state (Figure 9).
A role for IncG in PI3K-dependent protection against
apoptosis is suggested by the observation that the PI3K
inhibitor removed protection in cells infected with C.
trachomatis, but not in cells infected with C. pneumoniae, which
does not express the IncG protein. Phosphorylation of BAD
also appears to be necessary for co-localization with the
inclusion, since BAD does not co-localize with C. muridarum
inclusions at a time when little BAD is phosphorylated, even
though C. muridarum expresses IncG [32].
For safe measure, Chlamydia infection also leads to
degradation of most of the BAD protein [27,28], whose
degradation is measurable after 1 d of infection (Figure 9).
Any remaining, but presumably functional, BAD could be
sequestered away from mitochondria by 14-3-3b, via the
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chlamydial protein IncG, whose expression begins within 2 h
after internalization of the bacteria by host cells [32]. IncG is
also phosphorylated in infected cells, and the phosphoryla-
tion is required for IncG interaction with 14-3-3b [32].
Further exploration of the cross talk between chlamydial
inclusion membrane proteins and host-cell signaling path-
ways will likely yield valuable new information on Chlamydia-
dependent modulation of host-cell biology.
It is still unknown what mechanism could lead to PI3K
activation in C. trachomatis-infected cells. An obvious possi-
bility would be that chlamydiae secrete anti-apoptotic factors
through their type III secretion apparatus. Secreted bacterial
proteins of other pathogens can stimulate or interfere with
speciﬁc host-cellular processes for the beneﬁt of the
pathogen [48]. In particular, bacterial proteins secreted
through the type III secretion apparatus by a number of
pathogens have already been shown to modulate cell death
during infection [49–53]. Thus, Salmonella enterica protects
infected epithelial cells from apoptosis through secretion of
SopB, which induces sustained activation of AKT [53].
Figure 7. Localization of BAD and Phosphorylated BAD in Cells Infected with C. trachomatis or C. muridarum
(A) In order to visualize BAD by immunofluorescence, epithelial cells were transfected with the BAD expression plasmid prior to infection. Cells over-
expressing BAD were infected with C. trachomatis for 26 h and then incubated with 50 lM LY294002 (LY) or control buffer for 6 h before treating with 2
lM STS or control buffer overnight. BAD is localized to the surface of Chlamydia vacuoles in infected cells, with or without STS treatment (first and
second rows). The co-localization of BAD and Chlamydia vacuoles is lost in STS-treated infected cells that had been pre-incubated with LY294002
(bottom row).
(B) Cells over-expressing BAD were infected with C. trachomatis for 15 h and then incubated with control buffer (top row) or 50 lM LY294002 (LY)
(bottom row) for 6 h. Phosphorylated BAD is concentrated around the early Chlamydia vacuoles, but has a cytosolic distribution in infected cells after
treatment with LY294002. Cells treated with LY294002 were exposed at a longer time in order to visualize background phosphorylated-BAD staining.
(C) Cells over-expressing BAD were infected with C. muridarum for 15 h. BAD has a cytosolic distribution in infected cells, even in the absence of
LY294002. DNA was revealed with Hoechst (blue), Chlamydia with FITC-conjugated anti-Chlamydia antibody (green), and BAD with Texas Red-
conjugated anti-BAD antibody or phosphorylated BAD with Texas Red-conjugated antibody recognizing BAD phosphorylated on residue Ser136 (red). In
each case, one experiment of two representative experiments performed on separate days is shown.
DOI: 10.1371/journal.ppat.0020045.g007
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Alternatively or concurrently, a host-cell stress response
could result in PI3K activation. Signaling through AKT is
known to play a key role in protection of cells from a variety
of toxic stresses [38,54–58], as may occur during infection by
intracellular pathogens. In the speciﬁc case of Chlamydia,
infection is known to increase mitochondrial metabolism and
oxidative stress [59–61]. In cells exposed to oxidative stress,
down regulation of the PI3K/AKT pathway results in higher
levels of apoptosis [62] and oxidants stimulate the AKT
survival pathway [63,64]. Interestingly, mechanical stress,
which could be caused by the presence of a growing inclusion,
induces rapid phosphorylation of AKT in various cell types
[65,66]. We thus propose that Chlamydia could secrete speciﬁc,
as-yet-unidentiﬁed proteins that could activate the PI3K
pathway directly, or that oxidative or mechanical stress
induced by infection leads to activation of the host cell PI3K/
AKT pathway, resulting in protection from apoptosis.
Materials and Methods
Cells, bacteria, and chemical reagents. HeLa 299 cells (ATCC,
American Type Culture Collection, Manassas, Virginia, United States)
were cultured in a humidiﬁed incubator at 37 8C with 5% CO2 in
Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented with
glutamax-1 (Life Technologies Incorporated, Rockville, Maryland,
United States), 10% heat-inactivated fetal calf serum, and 25 lg/ml
gentamycin. The LGV/L2 strain of C. trachomatis and the TW-183
strain of C. pneumoniae were from the ATCC. The ‘‘mouse pneumo-
nitis’’ strain (MoPn), also known as C. muridarum, was a kind gift from
Dr. Roger Rank (University of Arkansas, Little Rock, Arkansas, United
States). The number of bacterial inclusion forming units was
determined using an immunoﬂuorescence method as previously
described [27,67]. The different signaling pathway inhibitors used in
this study (SP600125, SB203580, rapamycin, and KNK37) were from
Calbiochem (La Jolla, California, United States), except for LY294002,
which was from Sigma (St. Louis, Missouri, United States).
Cell culture and infection. HeLa cells growing at 70% conﬂuence
on tissue culture ﬂasks (Costar) were infected with the LGV/L2 strain
of C. trachomatis, C. muridarum, or C. pneumoniae at an MOI of 1.0 and
incubated for the indicated times in an incubator at 37 8C under 5%
CO2. Under these conditions, . 80% of the cells contained
chlamydial vacuoles after 1 d of infection. In order to induce
apoptosis, infected and control uninfected cells were treated over-
night with 2 lM STS (Sigma). When indicated, cells were incubated
with LY294002 before STS treatment. Both adherent cells and cells in
suspension were collected for either ﬂow cytometric or Western blot
analysis, while only adherent cells were ﬁxed for ﬂuorescence
microscopy.
Transfections. As BAD is not visible by immunoﬂuorescence in
cells expressing endogenous levels of BAD, BAD was over-expressed
where indicated. The BAD plasmid was transfected using Lipofect-
amine Plus reagent (Invitrogen Life Technology, Carlsbad, California,
United States) following manufacturer’s instructions. Brieﬂy, 12 h
after trypsinization and seeding into 24-well plates, HeLa cells were
incubated for 4 h at 37 8C with 250 ll of DMEM containing 400 ng of
pEBG-mBAD (Cell Signaling Technology, Beverly, Massachusetts,
United States), 1 ll of Lipofectamine, and 4 ll of Plus reagent. Serum-
containing medium was added into each well, and cells were
incubated for up to 48 h.
Transfection of siRNA for AKT was performed as follows: HeLa
cells were plated in 24 well-plates for 12 h before transfection in
order to reach 70% conﬂuence on the following day, when the
medium was replaced by 0.25 ml of serum-containing medium. The
siRNA complex was formed immediately before transfection by
adding 2.5 ll of the TransIT-TKO transfection reagent (Mirus
Corporation, Madison, Wisconsin, United States) drop-wise into 50
ll of serum-free RPMI 1640 (Invitrogen Life Technology). After
Figure 8. Localization of 14-3-3b in C. trachomatis-Infected Cells
Cells expressing endogenous levels of BAD were infected with C. trachomatis at an MOI of 1.0 for 26 h, and then incubated with 50 lM LY294002 (LY) or
control buffer for 6 h before treating with 2 lM STS overnight. DNA was revealed with Hoechst (blue), Chlamydia with FITC-conjugated anti-Chlamydia
antibody (green), and 14-3-3 with Texas Red-conjugated anti-14-3-3 antibody (red), as described in Materials and Methods. 14-3-3 is localized primarily
on the Chlamydia vacuole in infected cells, even in the presence of STS (top row). The co-localization of 14-3-3 and the Chlamydia vacuole is lost in
infected cells that had been pre-incubated with LY294002 before STS treatment (bottom row). One experiment of three representative experiments
performed on separate days is shown.
DOI: 10.1371/journal.ppat.0020045.g008
Figure 9. Summary of the Effects of C. trachomatis Infection on BAD
Phosphorylation, BAD Degradation, and Host-Cell Death
Infection with C. trachomatis leads to activation of PI3K, which in turns
results in AKT activation and subsequent BAD phosphorylation. In
parallel, infection causes degradation of most unphosphorylated BAD.
Simultaneous expression of IncG on the chlamydial inclusion and
binding of 14-3-3b by IncG allows the inclusion to recruit phosphorylated
BAD, preventing the ability of the remaining BAD to translocate to the
mitochondria and induce host-cell death.
DOI: 10.1371/journal.ppat.0020045.g009
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gentle mixing, the incubation was performed for 10 min at room
temperature. 50 nM siRNA AKT (ﬁnal concentration) was added to
the diluted transfection reagent, mixed gently, and incubated for 10
min at room temperature. Finally, 50 ll of this mixture was added to
each well, the plate was rocked gently, and further incubated for 48 h
at 37 8C. The sequences of the siRNA AKT were: sense, 59-
UGCCCUUCUACAACCAGGATT; antisense, 59-UCCUGGUUGUA-
GAAGGGCATT.
For pEGB m-BAD- or siRNA AKT-transfected and infected cells,
the infection with Chlamydia was begun 8 h after transfection. As a
negative control for siRNA AKT, cells were transfected with the same
amount of irrelevant RNA, before infection with Chlamydia.
Flow cytometric analysis of cytochrome c release. HeLa cells were
harvested with PBS containing 1% trypsin and 1 mM EDTA, and then
treated with digitonin (200 lg/ml) (Sigma) in PBS for 10 min on ice in
order to release cytosolic cytochrome c. Cells were washed with three
equivalent volumes of PBS containing 0.3% BSA, centrifuged (1,000
g, 10 min, 4 8C), and ﬁxed in 4% neutral-buffered paraformaldehyde
for 20 min at room temperature. Cells were then washed again in PBS
and incubated in blocking buffer (3% BSA, 0.1% Triton X-100 in
PBS) for 1 h. Finally, cells were incubated overnight at 4 8C with a
1:500 dilution of anti-cytochrome c monoclonal antibody (clone
6H2B4, BD Pharmingen, San Diego, United States). On the following
day, cells were washed three times with blocking buffer, and
incubated for 1 h with an FITC-conjugated goat anti-mouse antibody
(Caltag Laboratories, Burlingame, California, United States). The cells
were washed three times in PBS and analyzed by ﬂow cytometry (FL1),
as previously described [68].
Detection of apoptotic nuclei by Hoechst or TUNEL staining.HeLa
cells were grown on glass slides in 24-well plates, washed with PBS,
and ﬁxed in 4% neutral-buffered paraformaldehyde for 30 min. DNA
strand breaks were identiﬁed using a terminal deoxynucleotidyl-
transferase-mediated dUTP nick end labeling (TUNEL) assay kit,
following the manufacturer’s protocol (Roche Applied Science, Basel,
Switzerland), as previously described [69]. In order to detect infected
and apoptotic cells simultaneously, slides were counterstained using
an anti-Chlamydia genus monoclonal antibody (clone C5/C8, Argene
Biosoft, Varilhes, France) at 1:400 dilution, and a Texas Red-
conjugated or FITC-conjugated goat anti-mouse polyclonal antibody
(1:200 dilution) plus Hoechst (1 lg/ml) in PBS. Slides were mounted in
antifade medium (Dako, Glostrup, Denmark) and examined using an
epiﬂuorescence microscope (Zeiss Axioskope) equipped with band
pass optical ﬁlter sets appropriate for TRITC, FITC, and DAPI dyes.
The images were captured by multiple exposures using a cooled CCD
camera controlled by Metamorph software.
Cells were also stained with 1 lg/ml Hoechst, which detects both
host-cell and chlamydial DNA. In order to quantify the number of
apoptotic or non-apoptotic nuclei in both infected and uninfected
cells in each cell population, cells were counted in each microscope
ﬁeld, and the average and standard deviation per condition was
calculated for the % of apoptotic cells with co-localizing inclusions in
at least ten ﬁelds, containing an average of 100 cells per ﬁeld.
Localization of BAD, phosphorylated BAD, and 14-3-3b by
immunoﬂuorescence. BAD localization was detected on adherent
cells using rabbit anti-BAD antibody (Cell Signaling Technology) at
1:50 dilution, as described in the manufacturer’s protocol. Phos-
phorylated BAD was detected with an antibody recognizing BAD
phosphorylated on Ser136 (Santa Cruz Biotechnology, Santa Cruz,
California, United States). 14-3-3b was detected using a mouse anti-
14-3-3 antibody directly coupled to TRITC (clone C20; Santa Cruz
Biotechnology) diluted at 1:200 in PBS containing 3% BSA. Cells
were subsequently counterstained with Chlamydia antibody and
Hoechst (1 lg/ml), as described above.
Western blot analysis. Infected or uninfected cells were seeded in
12-well plates (Costar). Following transfection with either pEBG-
mBAD or AKT siRNA, or treatment with LY294002 and/or STS,
adherent cells and cells in suspension were pooled and washed in cold
PBS. Samples were lysed in Laemmli buffer containing both protease
(5 ll/ml, Sigma) and phosphatase inhibitor cocktails (5 ll/ml, Sigma)
before storing at 80 8C. Proteins were resolved on 12% SDS-PAGE
and transferred onto nitrocellulose membranes (Amersham Bio-
sciences, Little Chalfont, United Kingdom). After blocking in Tris-
buffered saline containing 0.05% Tween 20 (TBST) and 5% BSA, the
membranes were washed extensively in TBST and immunostained
with the following ﬁrst rabbit polyclonal antibodies diluted in
blocking buffer: anti-AKT antibody (1:1000) (from Cell Signaling
Technology), anti-AKT phosphorylated on Ser473 (1:1000) (Cell
Signaling Technology), anti-BAD (1:1000) (Cell Signaling Technol-
ogy), anti-BAD phosphorylated on Ser136 (1:500) (Cell Signaling
Technology), anti-BIM (Sigma), anti-tubulin (Sigma), or anti-p42/44
MAPK (1:1000) (Cell Signaling Technology). Following washes with
TBST, membranes were incubated with an anti-rabbit polyclonal
antibody conjugated to HRP diluted at 1:10000 (Amersham Bio-
sciences). Speciﬁc bands were visualized by enhanced chemilumines-
cence (Amersham Biosciences).
Statistics. Data are presented as the mean 6 standard deviation of
‘‘n’’ experiments. The statistical difference was determined using the
paired Student’s t test. A p value of less than 0.05 was considered
statistically signiﬁcant.
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